Regeneron Pharmaceuticals’ (REGN) “Neutral” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their neutral rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a report published on Wednesday morning, Benzinga reports. The brokerage currently has a $1,015.00 price objective on the biopharmaceutical company’s stock.

Several other equities research analysts also recently weighed in on the company. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,137.00 and set a “buy” rating for the company in a research note on Wednesday, October 16th. Morgan Stanley dropped their target price on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $1,260.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday. Finally, Argus boosted their price objective on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,101.00.

Regeneron Pharmaceuticals Trading Up 0.4 %

NASDAQ REGN opened at $933.02 on Wednesday. Regeneron Pharmaceuticals has a 52 week low of $769.19 and a 52 week high of $1,211.20. The company has a 50 day moving average price of $1,093.37 and a 200 day moving average price of $1,039.90. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The firm has a market cap of $102.86 billion, a PE ratio of 24.71, a price-to-earnings-growth ratio of 3.29 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period in the prior year, the firm posted $8.79 earnings per share. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals will post 37.66 EPS for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now directly owns 4,204 shares of the company’s stock, valued at $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Regeneron Pharmaceuticals by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock worth $8,595,268,000 after purchasing an additional 91,956 shares in the last quarter. Capital International Investors increased its holdings in shares of Regeneron Pharmaceuticals by 7.3% in the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after purchasing an additional 213,038 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after buying an additional 184,561 shares in the last quarter. International Assets Investment Management LLC boosted its stake in Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after buying an additional 879,916 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its holdings in Regeneron Pharmaceuticals by 12.4% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock valued at $567,864,000 after buying an additional 59,769 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.